<DOC>
	<DOCNO>NCT00896831</DOCNO>
	<brief_summary>The study aim assess effectiveness safety L-ornithine-L-aspartate management hepatic encephalopathy .</brief_summary>
	<brief_title>Therapeutic Efficacy Oral L-Ornithine-L-Aspartate Minimal Encephalopathy</brief_title>
	<detailed_description>Hepatic encephalopathy continue major clinical problem cirrhosis . Patients minimal hepatic encephalopathy risk accident , decline work performance , complain cognitive symptom , poor health-related quality life . This study compare L-ornithine-L-aspartate placebo 60 day assess effectiveness , safety health-related quality life drug .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>Cirrhosis diagnosis minimal hepatic encephalopathy use psychometric test critical flicker frequency Hepatic encephalopathy grade 1 4 Use drug treatment hepatic encephalopathy ( lactulose , neomycin ) Psychoactive substance use within 72 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>minimal hepatic encephalopathy</keyword>
	<keyword>L-ornithine-L-aspartate</keyword>
	<keyword>psychometric test</keyword>
	<keyword>critical flicker frequency</keyword>
	<keyword>quality life</keyword>
	<keyword>Treatment</keyword>
	<keyword>Health-related quality life</keyword>
</DOC>